BriaCell Therapeutics Corp. BCTX
Nov 3, 2026, 3:22 PM EST
- YTD
- -57.71%
- 1 year
- -69.94%
- Market cap
- 26.25M
- EPS (ttm)
- -6.97
- Shares out
- 44.20M
- Forward P/E
- -1.38
- YTD return
- -57.71%
- 1-year return
- -69.94%
- Volume
- 48.50K
- Avg volume
- 265.37K
- Open
- 3.12
- Previous close
- 3.09
- Day's range
- 3.00 – 3.18
- 52-week range
- 2.60 – 13.09
- Beta
- 1.82
- Analysts
- Strong Buy
- Price target
- 15.00 (+398.9%)
- Earnings date
- Oct 28, 2024
5D -0.49 (-13.46%)
Key statistics
- Enterprise value
- 9.95M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -10.83M
- Total cash
- 862.09K
- Total debt
- 0
- Return on equity
- 0.00%
- Short % of float
- 2.13%
- 50-day average
- 0.7918
- 200-day average
- 1.27
Analyst view
Consensus: strong buy
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Oct 28, 2024
Expected Oct 28, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 16, 2024 | Oct 1, 2024 | -0.08 | -0.22 | -0.14 | -175.00% |
| Oct 28, 2024 | Jul 1, 2024 | -0.52 | — | — | — |
| Oct 28, 2024 | Jul 1, 2024 | -0.52 | -0.07 | +0.45 | +86.54% |
| Jun 14, 2024 | Apr 1, 2024 | -0.55 | — | — | — |
| Jun 14, 2024 | Apr 1, 2024 | -0.55 | 0.11 | +0.66 | +120.00% |
| Mar 18, 2024 | Jan 1, 2024 | -0.20 | -0.71 | -0.51 | -255.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 3, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 19, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Sep 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- briacell.com
News
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer 
12 Health Care Stocks Moving In Thursday's Pre-Market Session 
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting 
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study 
Memorial Sloan Kettering Cancer Center Joins BriaCell’s Ongoing Pivotal Phase 3 Study Of Bria-IMT Plus Immune Checkpoint Inhibitor In Metastatic Breast Cancer 
BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center 
BriaCell Therapeutics Advances Bria-MEL+ Whole Cell Melanoma Immunotherapy Vaccine Candidate Toward Clinical Development With Key Genetic Engineering Milestone 
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™ 
BriaCell Therapeutics Receives FDA Clearance To Proceed With Clinical Evaluation Of Bria-PROS+, Its Next-Gen Personalized Off-The-Shelf Immunotherapy For Prostate Cancer 
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
Your note
Sign in to keep a note on BCTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Lustig (Marc) | 10% Security Holder of Issuer | Acquisition or disposition in the public market | Feb 16, 2022 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Lynwood Capital Management Inc. | 3.61% | 1,597,750 | 857.83K | Mar 30, 2024 |
| Vontobel Holding Limited | 0.18% | 80,000 | 42.95K | Sep 29, 2024 |
| HRT Financial LP | 0.17% | 74,286 | 39.88K | Sep 29, 2024 |
| Onyx Bridge Wealth Group, LLC | 0.11% | 50,000 | 26.84K | Sep 29, 2024 |
| Group One Trading, L.P. | 0.09% | 37,885 | 20.34K | Sep 29, 2024 |
| Summit Trail Advisors, LLC | 0.08% | 35,000 | 18.79K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.02% | 7,229 | 3.88K | Oct 30, 2024 |